HK1218750A1 - -雜芳基取代的吲唑 - Google Patents
-雜芳基取代的吲唑Info
- Publication number
- HK1218750A1 HK1218750A1 HK16106728.8A HK16106728A HK1218750A1 HK 1218750 A1 HK1218750 A1 HK 1218750A1 HK 16106728 A HK16106728 A HK 16106728A HK 1218750 A1 HK1218750 A1 HK 1218750A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- heteroaryl substituted
- substituted indazoles
- indazoles
- heteroaryl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160520 | 2013-03-21 | ||
| PCT/EP2014/055657 WO2014147203A1 (en) | 2013-03-21 | 2014-03-20 | 3-heteroaryl substituted indazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1218750A1 true HK1218750A1 (zh) | 2017-03-10 |
Family
ID=47901890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16106728.8A HK1218750A1 (zh) | 2013-03-21 | 2016-06-13 | -雜芳基取代的吲唑 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160046610A1 (zh) |
| EP (1) | EP2976336A1 (zh) |
| JP (1) | JP2016514718A (zh) |
| CN (1) | CN105209455A (zh) |
| AR (1) | AR095706A1 (zh) |
| CA (1) | CA2907592A1 (zh) |
| HK (1) | HK1218750A1 (zh) |
| TW (1) | TW201514166A (zh) |
| UY (1) | UY35500A (zh) |
| WO (1) | WO2014147203A1 (zh) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| US9643953B2 (en) | 2011-12-21 | 2017-05-09 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| CN105051030A (zh) * | 2013-03-21 | 2015-11-11 | 拜耳制药股份公司 | 二氨基杂芳基取代的吲唑 |
| JP2016514719A (ja) * | 2013-03-21 | 2016-05-23 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロアリール置換インダゾール |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2014202590A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2015063003A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2015103355A1 (en) | 2014-01-01 | 2015-07-09 | Medivation Technologies, Inc. | Compounds and methods of use |
| CA2952307A1 (en) | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| MX2017003664A (es) | 2014-09-19 | 2017-07-13 | Bayer Pharma AG | Indazoles sustituidos con benzilo como inhibidores de bub1. |
| US20170275270A1 (en) * | 2014-09-19 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles |
| AU2016212230B2 (en) | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| JP2018522847A (ja) | 2015-06-17 | 2018-08-16 | バイエル ファーマ アクチエンゲゼルシャフト | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| JP2019504826A (ja) * | 2015-12-16 | 2019-02-21 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| EP4217070A1 (en) | 2020-09-23 | 2023-08-02 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| BR112023006531A2 (pt) | 2020-10-09 | 2023-10-03 | Scorpion Therapeutics Inc | Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| EP4293019A1 (en) * | 2022-06-13 | 2023-12-20 | Netherlands Translational Research Center Holding B.V. | 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6837294B2 (en) * | 2003-02-10 | 2005-01-04 | Zipshade Industrial (B.V.I.) Corp. | Pull down, push up, shade assembly |
| DE602006017574D1 (de) * | 2005-07-26 | 2010-11-25 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare benzimidazole |
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2011115804A1 (en) * | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US9284298B2 (en) * | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| US9643953B2 (en) * | 2011-12-21 | 2017-05-09 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| ES2620316T3 (es) * | 2012-05-11 | 2017-06-28 | Bayer Pharma Aktiengesellschaft | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer |
| JP2016514719A (ja) * | 2013-03-21 | 2016-05-23 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロアリール置換インダゾール |
| CN105051030A (zh) * | 2013-03-21 | 2015-11-11 | 拜耳制药股份公司 | 二氨基杂芳基取代的吲唑 |
-
2014
- 2014-03-20 WO PCT/EP2014/055657 patent/WO2014147203A1/en active Application Filing
- 2014-03-20 CN CN201480029308.7A patent/CN105209455A/zh active Pending
- 2014-03-20 US US14/778,975 patent/US20160046610A1/en not_active Abandoned
- 2014-03-20 JP JP2016503668A patent/JP2016514718A/ja active Pending
- 2014-03-20 EP EP14714196.4A patent/EP2976336A1/en not_active Withdrawn
- 2014-03-20 CA CA2907592A patent/CA2907592A1/en not_active Abandoned
- 2014-03-21 TW TW103110770A patent/TW201514166A/zh unknown
- 2014-03-21 AR ARP140101319A patent/AR095706A1/es unknown
- 2014-03-24 UY UY0001035500A patent/UY35500A/es not_active Application Discontinuation
-
2016
- 2016-06-13 HK HK16106728.8A patent/HK1218750A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY35500A (es) | 2014-10-31 |
| WO2014147203A1 (en) | 2014-09-25 |
| EP2976336A1 (en) | 2016-01-27 |
| AR095706A1 (es) | 2015-11-04 |
| TW201514166A (zh) | 2015-04-16 |
| CA2907592A1 (en) | 2014-09-25 |
| JP2016514718A (ja) | 2016-05-23 |
| CN105209455A (zh) | 2015-12-30 |
| US20160046610A1 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218750A1 (zh) | -雜芳基取代的吲唑 | |
| HK1223350A1 (zh) | 雜芳基取代的吲唑 | |
| HK1222846A1 (zh) | 取代的苄基吡唑 | |
| HK1221717A1 (zh) | 取代的苄基吡唑 | |
| HK1217324A1 (zh) | 二氨基雜芳基取代的吲唑 | |
| HK1222852A1 (zh) | 二氨基雜芳基取代的吡唑 | |
| HRP20171890T1 (hr) | Supstituirani imidazopiridazini | |
| HK1222173A1 (zh) | 取代的吡唑並嘧啶基氨基-吲唑類 | |
| GB201518344D0 (en) | No details present | |
| HK1223362A1 (zh) | 取代的吡唑並吡啶胺 | |
| HK1220972A1 (zh) | 取代的噻唑並嘧啶 | |
| IL246271A0 (en) | Converted piperidinyl-tetrahydroquinolines | |
| DK3016978T3 (en) | Humane anti-ifn-alpha-antistoffer | |
| DK3016977T3 (en) | Humane anti-il-32-antistoffer | |
| GB201300632D0 (en) | Discovery | |
| HRP20180644T1 (hr) | Derivat pirazola | |
| SG11201510197RA (en) | Connecting Mechanism | |
| AU2013122V (en) | Sprilecflash Cordyline banksii | |
| AU2013123V (en) | Sprilecfire Cordyline banksii | |
| GB201318451D0 (en) | W/C Sani-vent | |
| GB201323054D0 (en) | No details | |
| GB201323055D0 (en) | No details | |
| GB201323056D0 (en) | No details | |
| GB201307081D0 (en) | Combines | |
| GB201307978D0 (en) | No details |